COMMUNIQUÉS West-GlobeNewswire

Predictive Oncology Inc. Announces Pricing of Public Offering of Up to $3,167,768.50 of Common Stock
02/10/2019
MINNEAPOLIS, Minn., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive” or “the Company”) today announced the pricing of its previously announced public offering of its common stock, [...]
Dabir Surfaces Inc. Announces Master Product Agreement with Trinity Health
02/10/2019
CHICAGO, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Dabir Surfaces Inc., a subsidiary of Methode Electronics Inc. (NYSE: MEI), focused on improving patient outcomes through the design and manufacture of an innovative solution [...]
REPEAT - AgraFlora Organics Reviews Delta Greenhouse Infrastructure Upgrades; Deploys Over C$30,000,000 in PPE Expenditures
02/10/2019
VANCOUVER, British Columbia, Oct. 02, 2019 (GLOBE NEWSWIRE) -- AgraFlora Organics International Inc. (“ AgraFlora ” or the “ Company ”) ( CSE: AGRA) (Frankfurt: PU31) (OTCPK: AGFAF ), a growth oriented and diversified [...]
AgraFlora Organics présente les améliorations réalisées sur l'infrastructure du Delta Greenhouse Complex incluant des dépenses en immobilisations corporelles de plus de 30 millions de dollars canadiens
02/10/2019
VANCOUVER, Colombie-Britannique, 02 oct. 2019 (GLOBE NEWSWIRE) -- AgraFlora Organics International Inc. (« AgraFlora » ou la « Société ») (CSE: AGRA) (Frankfurt: PU31) (OTCPK: AGFAF) une société internationale de [...]
Celldex Therapeutics Announces Upcoming Data Presentations
02/10/2019
HAMPTON, N.J., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that multiple Company drug development programs will be the subject of presentations at upcoming medical and [...]
BioCardia Announces the Appointment of Two New Board Members
02/10/2019
SAN CARLOS, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the appointment of [...]
Cue Biopharma to Present Corporate Overview and Update on Clinical Development Progress for CUE-101 at the Cantor 2019 Global Healthcare Conference
02/10/2019
CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate [...]
Demant A/S: Change of date of publication of Interim Management Statement
02/10/2019
Company announcement no 2019- 12 2 October 2019 Change of date of publication of Interim Management Statement The date of publication of Demant’s Interim Management Statement has been changed from 7 November to 18 [...]
AgraFlora Organics Reviews Delta Greenhouse Infrastructure Upgrades; Deploys Over C$30,000,000 in PPE Expenditures
02/10/2019
VANCOUVER, British Columbia, Oct. 02, 2019 (GLOBE NEWSWIRE) -- AgraFlora Organics International Inc. (“ AgraFlora ” or the “ Company ”) ( CSE: AGRA) (Frankfurt: PU31) (OTCPK: AGFAF ), a growth oriented and diversified [...]
New Data Presented on ASLAN’s varlitinib at ESMO 2019
02/10/2019
SINGAPORE, Oct. 02, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced the presentation of new data from a phase [...]
Nexstim Plc in Technology Licensing Discussions with a Leading California Based Academic Institution
02/10/2019
Company announcement, Helsinki 2 October 2019 at 9.00 AM (EEST) Nexstim Plc in Technology Licensing Discussions with a Leading California Based Academic Institution Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or " [...]
Top Line Results from Glaucoma Dolomites Phase 2 Trial Show Nicox’s NCX 470 Meets Primary Endpoint and Demonstrates Statistical Superiority vs Latanoprost
02/10/2019
Press Release Top Line Results from Glaucoma Dolomites Phase 2 Trial Show Nicox’s NCX 470 Meets Primary Endpoint and Demonstrates Statistical Superiority vs Latanoprost NCX 470 met the primary endpoint of non- [...]
Nicox : Les premiers résultats de l’étude de phase 2 Dolomites dans le glaucome montrent que le NCX 470 atteint le critère d’évaluation primaire et démontre une supériorité statistique vs. latanoprost
02/10/2019
Communiqué de presse Nicox : Les premiers résultats de l’étude de phase 2 Dolomites dans le glaucome montrent que le NCX 470 atteint le critère d’évaluation primaire et démontre une supériorité statistique vs. [...]
Bone Therapeutics to present preclinical data on the osteogenic properties of ALLOB in bone repair at 27th Annual Meeting of the European Orthopaedic Research Society
02/10/2019
Press release Gosselies, Belgium, 2 October 2019, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the development of innovative cell and biological therapies to [...]
Bone Therapeutics présentera des données précliniques sur les propriétés ostéogéniques d’ALLOB dans la régénération osseuse à l’occasion de la 27e réunion annuelle de l’EORS (European Orthopaedic Research Society)
02/10/2019
Communiqué de presse Gosselies, Belgique, le 2 octobre 2019, 07h00 CEST – BONE THERAPEUTICS (Euronext Bruxelles et Paris : BOTHE, éligible PEA-PME), société de biotechnologie spécialisée dans le développement de [...]
Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
02/10/2019
Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA)[1] Novartis plans FDA submission for nr-axSpA, having [...]
Novadip Biosciences Presents Clinical Case Study on Next Generation Tissue Regeneration Therapy for Critical Size Bone Reconstruction at EORS Conference
02/10/2019
Novadip Biosciences Presents Clinical Case Study on Next Generation Tissue Regeneration Therapy for Critical Size Bone Reconstruction at EORS Conference Study highlights potential benefit in rare pediatric orthopedic [...]
BriaCell Therapeutics Corp. to Clarify Record Date
02/10/2019
BERKELEY, Calif. and VANCOUVER, British Columbia, Oct. 01, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company [...]
NextCure to Present Clinical Data from NC318 Phase 1/2 Clinical Trial at 34th Annual Meeting of SITC
02/10/2019
BELTSVILLE, Md., Oct. 01, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer [...]

Pages